Abstract
The secretin/PACAP/VIP superfamily contains at least ten brain-gut peptides, including secretin, pituitary adenylate cyclase-activating polypeptide (PACAP), vasoactive intestinal polypeptide (VIP), glucagon, glucagon-like peptide-1 (GLP-1), glucagon like peptide-2 (GLP-2), gastric inhibitory polypeptide (GIP), peptide histidine isoleucine (PHI) or peptide histidine methionine (PHM), and growth hormone-releasing hormone (GHRH). These peptides exhibit a wide tissue distribution in the peripheral systems, indicating their pleiotrophic actions in the body. Meanwhile, their functions in the central nervious system (CNS) have also been consolidated recently. For instance, most of these peptides have shown to serve as neurotransmitters, neuromodulators, neurotrophic factors, and/or neurohormones in the brain, and hence, their potential as novel CNS agents in treating neurological disorders including Autism, Alzheimers disease, Parkinsons disease and HIV-associated neuronal cell death were recently exploited. In this article, recent progress in research of peptides in this family with particular emphasis on structures, their central functions and potential use in the treatment of neuronal diseases are reviewed.
Keywords: Secretin/VIP/PACAP family peptides, chemical structure, central nervous system, physiological actions, neuropathological diseases
Central Nervous System Agents in Medicinal Chemistry
Title: The Secretin/Pituitary Adenylate Cyclase-Activating Polypeptide/ Vasoactive Intestinal Polypeptide Superfamily in the Central Nervous System
Volume: 6 Issue: 1
Author(s): J. Y.S. Chu, L. T.O. Lee, F. K.Y. Siu and B. K.C. Chow
Affiliation:
Keywords: Secretin/VIP/PACAP family peptides, chemical structure, central nervous system, physiological actions, neuropathological diseases
Abstract: The secretin/PACAP/VIP superfamily contains at least ten brain-gut peptides, including secretin, pituitary adenylate cyclase-activating polypeptide (PACAP), vasoactive intestinal polypeptide (VIP), glucagon, glucagon-like peptide-1 (GLP-1), glucagon like peptide-2 (GLP-2), gastric inhibitory polypeptide (GIP), peptide histidine isoleucine (PHI) or peptide histidine methionine (PHM), and growth hormone-releasing hormone (GHRH). These peptides exhibit a wide tissue distribution in the peripheral systems, indicating their pleiotrophic actions in the body. Meanwhile, their functions in the central nervious system (CNS) have also been consolidated recently. For instance, most of these peptides have shown to serve as neurotransmitters, neuromodulators, neurotrophic factors, and/or neurohormones in the brain, and hence, their potential as novel CNS agents in treating neurological disorders including Autism, Alzheimers disease, Parkinsons disease and HIV-associated neuronal cell death were recently exploited. In this article, recent progress in research of peptides in this family with particular emphasis on structures, their central functions and potential use in the treatment of neuronal diseases are reviewed.
Export Options
About this article
Cite this article as:
Chu Y.S. J., Lee T.O. L., Siu K.Y. F. and Chow K.C. B., The Secretin/Pituitary Adenylate Cyclase-Activating Polypeptide/ Vasoactive Intestinal Polypeptide Superfamily in the Central Nervous System, Central Nervous System Agents in Medicinal Chemistry 2006; 6 (1) . https://dx.doi.org/10.2174/187152406776056546
DOI https://dx.doi.org/10.2174/187152406776056546 |
Print ISSN 1871-5249 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6166 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Peptides in Oral Diseases
Current Pharmaceutical Design Hypersensitivity Reactions to Neuromuscular Blocking Agents
Current Pharmaceutical Design Thrombotic Thrombocytopenic Purpura, from the Perspectives of a Pediatrician
Current Pediatric Reviews New Approaches to Endothelin Receptor Antagonist-Bosentan
Letters in Organic Chemistry GPR55 and its Interaction with Membrane Lipids: Comparison with Other Endocannabinoid-Binding Receptors
Current Medicinal Chemistry Genomics of Addiction
Current Psychiatry Reviews Targeting NO Signaling for the Treatment of Osteoporosis
Current Medicinal Chemistry The Role of Topical Growth Factors in Chronic Wounds
Current Drug Delivery The Roles of Neurotensin and its Analogues in Pain
Current Pharmaceutical Design Platelets and Atherothrombosis: Causes, Targets and Treatments for Thrombosis
Current Medicinal Chemistry Guanylation of Amines with Isonitriles in the Presence of Iodine
Letters in Organic Chemistry Non-Analgesic Effects of Opioids: Neuroprotection in the Retina
Current Pharmaceutical Design NO News is not Necessarily Good News in Cancer
Current Cancer Drug Targets Neuroprotection and Sex Steroid Hormones: Evidence of Estradiol- Mediated Protection in Hypertensive Encephalopathy
Mini-Reviews in Medicinal Chemistry The Influence of Traumatic Lumbar Puncture (TLP) on Outcome of Pediatric Patients
Current Pediatric Reviews Propranolol Safety Profile in Children
Current Drug Safety Genetic Characterization of Lactic Acid Bacteria Isolated from Tunisian Milk Waste and their Antimicrobial Activity Against some Bacteria Implicated in Nosocomial Infections
Infectious Disorders - Drug Targets Plant Terpenes on Treating Cardiovascular and Metabolic Disease: A Review
Protein & Peptide Letters Sildenafil is Well Tolerated by Erectile Dysfunction Patients Taking Antihypertensive Medications, Including Those on Multidrug Regimens
Current Drug Safety Snake Venom Phospholipases A2: A Novel Tool Against Bacterial Diseases
Current Medicinal Chemistry